PALB2 and prostate carcinoma: Several germline mutations and variants of FA pathway genes have been reported as risk factors in cancer in non-FA patients/individuals; namely, mutations in BRCA1 (FANCS), PALB2 (FANCN), and BRCA2 (FANCD1) have been shown to lead to increased risk of breast and ovarian cancers, as well as prostate cancer (18–20).